Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

OTHER 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Spinal Cord Neoplasms 1Rhabdoid Tumor 1Pheochromocytoma 1Paraganglioma, Extra-Adrenal 1Paraganglioma 1Optic Nerve Glioma 1Oligodendroglioma 1Neuroblastoma 1Medulloblastoma 1Familial ependymoma 1Choroid Plexus Neoplasms 1Carcinoma, Medullary 1Astrocytoma 1Adenocarcinoma, Follicular 1

Interventions

3-Iodobenzylguanidine 8lutetium Lu 177 dotatate 6gallium Ga 68 dotatate 5Temozolomide 4Specimen Handling 4Magnetic Resonance Spectroscopy 4anlotinib 3Everolimus 3olaparib 2cabozantinib 2belzutifan 2Sunitinib 2Phenoxybenzamine 2Nivolumab 2Fluorodeoxyglucose F18 2Biopsy 2Axitinib 23-fluorobenzylguanidine 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2vandetanib 1talazoparib 1spartalizumab 1pembrolizumab 1pazopanib 1lanreotide 1guadecitabine 1fluorodopa F 18 1fludarabine phosphate 1copper dotatate CU-64 1cixutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paraganglioma × Vorinostat × Endocrine × Clear all
NCT01838187 2023-08-18

Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Children's Hospital Medical Center, Cincinnati

No longer available
CNSEndocrine

Neuroblastoma, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡